The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study

Background Hepatitis B e antigen (HBeAg)-negative inactive carriers, the majority of hepatitis B virus (HBV) carriers, are considered to have a good prognosis. The definition of the inactive HBV carrier state has been based on HBV DNA and alanine aminotransferase (ALT) levels. Here we conducted a pr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology 2017-01, Vol.52 (1), p.113-122
Main Authors: Taida, Takashi, Arai, Makoto, Kanda, Tatsuo, Hige, Shuhei, Ueno, Yoshiyuki, Imazeki, Fumio, Izumi, Namiki, Tanaka, Eiji, Shinkai, Noboru, Yoshioka, Kentaro, Nakamoto, Yasunari, Nishiguchi, Shuhei, Tsuge, Masataka, Abe, Masanori, Sata, Michio, Yatsuhashi, Hiroshi, Ido, Akio, Kita, Kazuhiko, Azemoto, Ryousaku, Kitsukawa, Yoshio, Goto, Nobuaki, Yokosuka, Osamu
Format: Article
Language:English
Subjects:
Abdominal Surgery
Adult
Aged
Alanine Transaminase - blood
Analysis
Biliary Tract
Carrier State - virology
Cohort Studies
Colorectal Surgery
Development and progression
DNA, Viral - blood
Female
Follow-Up Studies
Gastroenterology
Hepatitis B
Hepatitis B - virology
Hepatitis B e Antigens - blood
Hepatitis B virus
Hepatology
Humans
Japan
Liver
Liver cirrhosis
Male
Medicine
Medicine & Public Health
Middle Aged
Original Article—Liver
Pancreas
Prognosis
Prospective Studies
Surgical Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Hepatitis B e antigen (HBeAg)-negative inactive carriers, the majority of hepatitis B virus (HBV) carriers, are considered to have a good prognosis. The definition of the inactive HBV carrier state has been based on HBV DNA and alanine aminotransferase (ALT) levels. Here we conducted a prospective study involving 18 hospitals to clarify the prognosis of HBeAg-negative inactive carriers. Methods Three hundred eighty-eight HBeAg-negative inactive carriers at the baseline were observed prospectively from January 2011 to November 2015. We evaluated the primary end point, defined as the development of cirrhosis, hepatocellular carcinoma (HCC), or liver-related death. Also, we analyzed the factors associated with inactive carrier dropout and markedly increased levels of ALT or HBV DNA or both during the follow-up period. Results At the baseline, the mean age was 57.5 ± 13.1 years and 42 % of patients were male. No individual developed cirrhosis, HCC, or liver-related death during the follow-up period (1035 ± 252 days). Loss of inactive carrier status was seen in 75 patients (19.3 %). Factors associated with failure to meet the inactive carrier criteria in the multivariate analysis were the levels of ALT (hazard ratio 1.13, 95 % confidence interval 1.07–1.19, p  
ISSN:0944-1174
1435-5922
DOI:10.1007/s00535-016-1229-6